Information  X 
Enter a valid email address

MaxCyteInc $0.01DI (MXCT)

Related News

10-May-2022 12:01 PM

IN BRIEF: MaxCyte first-quarter loss narrows; raises annual guidance

MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says is pleased with positive start to 2022 with ‘very strong’ first-quarter results. For three months to March 31, posts net loss $4.1 million, narrowed from
23-Mar-2022 05:22 PM

MaxCyte widens net loss in 2021 while annual revenue increases

MaxCyte Inc on Wednesday posted a widened net loss of $19.1 million in 2021, increased from a loss of $11.8 million the year before. Revenue increased by 30% to $33.9 million from $26.2 million. The Maryland-based platfo
10-Mar-2022 03:57 PM

IN BRIEF: MaxCyte hires chief scientist from Stemson Therapeutics

MaxCyte Inc - Maryland-based platform for cell-based research - Hires Cenk Sumen as chief scientific officer. Sumen joins from San Diego, California-based hair-loss treatment firm Stemson Therapeutics Corp, where he was chief technology officer.
14-May-2021 08:52 AM

MaxCyte files draft registration with SEC for dual-listing on Nasdaq

MaxCyte, a leading provider of platform technologies for battery engineering, has submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission, paving the way for a proposed dual-listing and public offering of shares of
20-Apr-2021 09:42 AM

MaxCyte books loss as expenses offset 21% rise in revenue

Cell-based therapies group MaxCyte booked a full-year loss after a rise in revenue was more than offset by R&D and marketing spending. Net losses for the year through December amounted to $11.8 million, compared to year-on-year losses of $12.9 million.
20-Jan-2021 10:00 AM

MaxCyte annual revenue seen rising 21%; beating expectations

Cell-based therapy company MaxCyte said it had performed ahead of market expectations in 2020, with revenue expected to rise 21%. Revenue for the year through December would be around $26.2 million, up from $21.6 million in 2019. 'While Covid-19 ha
23-Dec-2020 07:26 AM

MaxCyte expects annual financial results to beat market expectations

Cell-based therapies group MaxCyte said it expected annual financial results at its core life sciences business to be ahead of market expectations. MaxCyte said the upgrade, for the year through December, was based on ongoing momentum in transformationa
21-Sep-2020 08:00 AM

MaxCyte books first-half loss; upgrades annual revenue outlook

Cell-based therapies developer MaxCyte booked a first-half loss, as a rise in revenue was offset by R&D and marketing spending. Net losses for the six months through June amounted to $6.1m, compared to losses of $9.5m on-year. Revenue rose 30% to $10.9m
15-Jul-2020 08:56 AM

MaxCyte sees first-half revenue rising 30%

Cell-based therapy developer MaxCyte said it expected its first-half revenue to rise about 30%, reflecting increased adoption and usage of its products by its client based. MaxCyte said the growth in sales represented an acceleration on the growth rate s
21-Apr-2020 08:00 AM

MaxCyte losses deepen on R&D spend; revenue beats expectations

Cell-based therapies developer MaxCyte booked a deeper annual loss after it upped spending on R&D, though its sales were higher than hoped. Net losses for the year through December amounted to $12.9m, compared to losses of $8.9m on-year. Revenue rose 30
20-Jan-2020 07:52 AM

MaxCyte beats market expectations with 30% revenue improvement

Cell-based therapies company MaxCyte said it was trading ahead of market expectations, as sales growth accelerated in the second half. Revenue for the year through December was expected to rise about 30% to $21.6m, having jumped 36% in the second half.
18-Sep-2019 02:33 PM

MaxCyte losses deepen after higher R&D spend

Cell-based therapies and life sciences company MaxCyte booked a deeper first-half loss after rising revenue was more than offset by higher R&D and marketing costs. Pre-tax losses for the six months through June amounted to $9.5m, compared to losses of $4
17-Jul-2019 07:52 AM

MaxCyte sees first-half revenue rising 21%

Cell-based therapies company MaxCyte said its revenue in the first half was expected to grow by 21%. Revenue for the six months through June was seen rising to $8.4m, up from $6.9m on-year. 'MaxCyte continues to build upon its substantial momentum
24-Apr-2019 07:52 AM

MaxCyte books annual loss owing to R&D, marketing spending

Cell-based medicines group MaxCyte booked a full-year loss after rising sales were more than offset by spending, including on R&D and marketing. Net losses for the year through December amounted to $8.9m, compared to losses of $9.9m on-year. Revenue ros
15-Jan-2019 07:52 AM

MaxCyte expects annual earnings beat as revenue rises 19%

Cell-based medicines company MaxCyte said it expected to post annual operating earnings ahead of market expectations after it sales rose by almost a fifth. Revenue for the year through December was seen rising by around 19% to $16.7m, the company said.
21-May-2018 09:26 AM

MaxCyte presents positive trial data for sickle cell disease treatment

MaxCyte said it had presented positive results from a pre-clinical trial of a treatment for sickle cell disease at a conference in Chicago. The new data were released in a poster presentation on Friday at the American Society of Gene and Cell Therapy. &
22-Jan-2018 09:11 AM

MaxCyte forecasts 14% revenue rise

Cell-based medicine developer MaxCyte said it expected to post a 14% increase in annual revenue to around $14m. Ebitda for the period was expected to be in line with market expectations, while cash and cash equivalents at the year-end were $25.3m, it sai
31-Oct-2017 01:00 PM

All reslolutions passed at AGM of MaxCyte

MaxCyte has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:00pm: (LON:MXCR) Maxcyte Inc Com Stk Usd0.01 Direg S share price was 0p at 247.5p (LON:MXCT) MaxCyte Inc share price was 0p at 245p
25-Apr-2017 12:40 PM

Broker Forecast - Panmure Gordon issues a broker note on MaxCyte Inc

Panmure Gordon today reaffirms its buy investment rating on MaxCyte Inc (LON:MXCT) and cut its price target to 338p (from 349p). Story provided by StockMarketWire.com...
31-Mar-2017 02:05 PM

MaxCyte raises £20m via placing

MaxCyte has announced that it has successfully placed 7,275,000 new shares at 275p each, raising around £20m. Doug Doerfler, President & Chief Executive Officer, said: "This is an exciting period for MaxCyte and the proceeds from this fundrais
20-Mar-2017 10:20 AM

Broker Forecast - Panmure Gordon issues a broker note on MaxCyte Inc

Panmure Gordon today reaffirms its buy investment rating on MaxCyte Inc (LON:MXCT) and raised its price target to 349p (from 280p). Story provided by StockMarketWire.com...
27-Sep-2016 09:45 AM

MaxCyte posts H1 results

MaxCyte has posted its financial results for the six months ended 30 June 2016. The highlights are: - Revenues of $5.5 million for the six months ended 30 June 2016, a 30.3% increase over $4.2 million for the same period of 2015 - Gross margins remained
31-Aug-2016 03:46 PM

MaxCyte Plc to present at the Shares Investor Evening in London on 27th September 2016

Doug Doerfler, President & CEO of MaxCyte (MXCT) (LSE:MXCT) will be giving a briefing at the Shares Investor Evening on 27th September 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by
10-May-2016 10:51 AM

MaxCyte posts narrower FY net loss

MaxCyte has booked a narrower FY net loss of USD1.45m, from a loss of USD1.84m. Revenue improved to USD9.3m, from USD7.2m. Higher operating expenses -- particularly R&D and sales and marketing -- were a factor. Total assets were USD6.4m at-2015, from USD

a d v e r t i s e m e n t